Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI) / Previously Known as: Administration of Neomycin Resistance Gene Marked LMP2A-Specific Cytotoxic T-Lymphocytes to Patents With Relapsed EBV-Positive Lymphoma (ALASCAR)

NCT00062868 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT00062868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00062868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of LMP-Specific Cytotoxic T-Lymphocytes to Patients With Relapsed EBV-Positive Lymphoma (ALCI) / Previously Known as: Administration of Neomycin Resistance Gene Marked LMP2A-Specific Cytotoxic T-Lymphocytes to Patents With Relapsed EBV-Positive Lymphoma (ALASCAR)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2003
Completion date
April 30, 2020
Enrollment
74 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease, leiomyosarcoma, lymphoepithelioma, non hodgkin lymphoma